If you are a sales professional or want to become one, or if you are looking for a new sales job, you will face one of the toughest interview processes of any job seeker.
MALVERN, PA - (HSMN NewsFeed) - Auxilium Pharmaceuticals, Inc. (NASDAQ:AUXL ), a specialty biopharmaceutical company, today announced that the U.S. Food and Drug Administration’s (FDA) Arthritis Advisory Committee confirmed it will review XIAFLEX(TM) durin…
Biopharmaceuticals, FDA
Auxilium Pharmaceuticals, XIAFLEX, collagenase, Dupuytren’s
Posts from ‘July, 2009’
U.S. Food and Drug Administration’s Arthritis Advisory Committee Confirms Date to Review XIAFLEX(TM) for the Treatment of Dupuytren’s Contracture
Thoratec Corporation and HeartWare International, Inc. Announce Termination of Proposed Transaction
PLEASANTON, Calif., FRAMINGHAM, Mass. and SYDNEY, July 31 (HSMN NewsFeed) — Thoratec Corporation (Nasdaq: THOR ), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, and HeartWare Internat…
Devices, Cardiology, Mergers & Acquisitions
Thoratec, HeartWare International
BSD Clinical Hyperthermia System Integrated with GE Healthcare MR System at Duke University School of Medicine
SALT LAKE CITY, July 31–(HSMN NewsFeed)–BSD Medical Corporation (NASDAQ: BSDM ) (www.bsdmedical.com) announced today that the Company has completed integration of a BSD-2000/3D/MR Hyperthermia System with a GE Healthcare (GE) 1.5 Tesla magnetic resonance…
Devices, Oncology, Radiology
BSD Medical, GE Healthcare, BSD-2000, hyperthermia
PharmaForce Inc. Receives FDA Approval for First Generic of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension, USP
COLUMBUS, Ohio, July 31 (HSMN NewsFeed) — PharmaForce, Inc., announced today that it has received approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Betamethasone Sodium Phosphate and Betamethas…
Biopharmaceuticals, Generics, FDA
PharmaForce, Betamethasone, Schering, Celestone, Soluspan
Cephalon Appoints Craig C. Phillips as Vice President and General Manager of Oncology Business Unit
FRAZER, Pa., July 31 (HSMN NewsFeed) — Cephalon, Inc. (Nasdaq: CEPH ) announced today that Craig C. Phillips has been appointed as Vice President and General Manager of the Oncology Business Unit. In this role, Phillips will have responsibility for mana…
Biopharmaceuticals, Oncology, Personnel
Cephalon
QuantRx(R) Forms Joint Venture with NuRx for the Global Launch of Innovative Point-of-Care Products
Significant Funding Received to Support Growth Initiatives DOYLESTOWN, Pa.–(HSMN NewsFeed)–QuantRx Biomedical Corporation (OTCBB: QTXB) announced today the creation of a joint venture with NuRx Pharmaceuticals, Inc. (OTCBB: NUXP) to accelerate efforts…
Diagnostics
QuantRx Biomedical, NuRx Pharmaceuticals, QN Diagnostics, RapidSense
AGA Pharmaceutical Patent Declared Valid in U.K. Patent Infringement Lawsuit against Occlutech
MINNEAPOLIS, July 31–(HSMN NewsFeed)–AGA Medical Holdings, Inc. (AGA) today announced that a U.K. court has determined that an AGA-held patent for its Atrial Septal Defects (ASD) and Patent Foramen Ovale (PFO) devices is valid. However, the U.K. court de…
Devices, Cardiology, Litigation
AGA Pharmaceutical, Occlutech, Atrial Septal Defect, Patent Foramen Ovale
Second Phase III Study Showed Lucentis Improved Vision in Patients With Retinal Vein Occlusion
SOUTH SAN FRANCISCO, Calif.–(HSMN NewsFeed)–Genentech, Inc., a wholly-owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the Phase III study CRUISE showed Lucentis(R) (ranibizumab injection) improved vision, as measured by…
Biopharmaceuticals, Ophthalmology
Genentech, Lucentis, ranibizumab, macular edema, retinal vein occlusion
FDA Approves Sculptra(R)Aesthetic, a Facial Injectable for Correction of Nasolabial Folds and Other Facial Wrinkles
BRIDGEWATER, N.J., July 29 (HSMN NewsFeed) — Sanofi-aventis U.S. announced today that the U.S. Food and Drug Administration (FDA) approved Sculptra®Aesthetic (injectable poly-L-lactic acid) for the correction of shallow to deep nasolabial fold (smil…
Biopharmaceuticals, Dermatology, FDA
sanofi-aventis, SculptraAesthetic, poly-L-lactic acid, nasolabial fold
Massachusetts General Hospital to install IMRISneuro
Leadership in Neuroscience Continues with New Imaging System WINNIPEG, July 29 –(HSMN NewsFeed)– IMRIS Inc. (TSX: IM ; "IMRIS" or the "Company") announced today that Massachusetts General Hospital has selected IMRISneuro as the lat…
Devices, Neurosurgery, Radiology
IMRIS, IMRISneuro, intra-operative MR, magnetic resonance imaging, imaging
